|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
FSP 2015 Summer Anatomic Pathology Conference!
You don't want to miss the great topics and speakers scheduled for the FSP 2015 Summer Anatomic Pathology Conference. The event will take place July 25-26, 2015, at The Boca Raton Resort in Florida. More information will be available soon at www.flpath.org.
Andrew E. Rosenberg, M.D.
University of Miami Hospital
William Westra, M.D.
Johns Hopkins Medical Institute
Cesar Moran, M.D.
The University of Texas MD Anderson Cancer Center
2 American diagnostics labs get hit with a $48.5 million fine for providing unnecessary medical tests
The Standard Daily
Two U.S. companies have been slammed with a joint $48.5 million fine for conducting unnecessary medical tests in affinity with doctors that refer patients to them for a commission. The companies are Health Diagnostics Laboratory (HDL) and Singulex, two cardiovascular disease testing labs. HDL is fined the sum of $47 and Singulex is to pay back $1.5 million; but then, neither of the companies admitted any guilt or liability in the lawsuit brought against them.
Medicare has new goals and deadlines for transitioning from fee-for-service healthcare models to value-based reimbursement
What happens to pathologists and clinical laboratories when fee-for-service reimbursement ceases to be the primary payment method for anatomic pathology services and medical laboratory tests? After all, fee-for-service reimbursement for lab tests is what underpins today’s financial model for lab test services. Under this transaction-based business arrangement, a clinical laboratory that can increase its specimen volume will realize a lower average cost-per-test because of economies of scale within the lab. At the same time, the lower costs mean a bigger net margin available from profit, given the fixed price of the reimbursement for lab tests.
Match Day for medical residency: The scramble, foreign doctors and a shortage
What's the most dramatic day of medical school? It's not the first day of anatomy lab, when students cut into cadavers, or the beginning of rotations, when they meet patients for the first time. It's match day — the day when soon-to-be doctors find out where they will complete their residencies. Match Day is the culmination of a grueling process.
Biomarker set forms the basis for new blood test to detect colorectal cancer
Colorectal cancer is the third most common form of cancer globally and the second most common cause of cancer deaths. The chance of a cure is high if the cancer is detected early enough, but early detection is not a given. Researchers from VIB and KU Leuven — together with various European oncology centers, including UZ Leuven — have identified biomarkers that can be incorporated in a new diagnostic test. This should make it possible to detect colorectal cancer in an early stage using a simple blood test.
Potential new biomarker for aggressive prostate cancer identified
Medical News Today
Researchers from the University of Michigan investigating bone formation have made a surprise discovery with the potential to be a breakthrough in the study of prostate cancer. The team has discovered a previously unidentified biomarker that could affect the diagnosis and treatment of the disease.
Miss an issue of Pathology Today? Click here to visit the Pathology Today archive page.
New, cross-sector collaboration aims to discover clinical biomarker for pancreatic cancer
The search to discover and validate the first-ever clinical biomarker to diagnose and treat pancreatic cancer is at the foundation of a new, cross-sector collaboration. Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach; the Cancer Center at Beth Israel Deaconess Medical Center, a Harvard Medical School teaching hospital, and the Pancreatic Cancer Research Team managed by Cancer Research And Biostatistics announced they will work together to eradicate the disease.
23andMe CEO on the future of genomics
The Human Genome Project, completed in 2003, single-handedly transformed science and medicine. Thanks to DNA sequencing technology we are learning more about human health than ever before, gaining insight into complex diseases and unlocking mysteries about human evolution and ancestry. Anne Wojcicki, founder and CEO of 23andMe, is one of the pioneers in the booming genomics industry.
Study examines diagnostic accuracy of pathologists interpreting breast biopsies
In a study in which pathologists provided diagnostic interpretation of breast biopsy slides, overall agreement between the individual pathologists' interpretations and that of an expert consensus panel was 75 percent, with the highest level of concordance for invasive breast cancer and lower levels of concordance for ductal carcinoma in situ and atypical hyperplasia, according to a study in the March 17 issue of JAMA.
Quintiles, Quest diagnostics form lab services joint venture
Quintiles Transnational Holdings Inc. and Quest Diagnostics Inc. agreed to pool their clinical-trial services for drugmakers into a joint venture. Quintiles will own 60 percent and Quest the rest of the venture, which would have earned $575 million in revenue had it existed last year, the companies said in a statement. The combination creates the world's second-largest provider of central laboratory services, they said. Laboratory Corporation of America Holdings is the biggest.
Disclaimer: The authors, editors, and the Florida Society of Pathologists (FSP) Executive Committee affiliated with "Florida Pathology Today" e-Newsletter cannot and do not warrant the completeness, accuracy, non-infringement, merchantability, timeliness or fitness for a particular purpose of the information or views contained within this publication, or available through the links provided within articles contained within this publication.
FSP has no control over and does not officially endorse the content of the information available on the links contained in the "Florida Pathology Today" or links imbedded in articles within the "Florida Pathology Today." These links are provided as a courtesy only. Linked sites are not a part of the "Florida Pathology Today." The owners of those linked sites, and not FSP, own the intellectual property rights to the material on the linked sites. FSP cannot certify the accuracy of material published on linked sites. Additionally, the contents of this e-Newsletter and the above referenced links, including any advice, suggestions, and/or recommendations have NOT been generated as part of any professional evaluation.
The authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" e-Newsletter shall not be liable to anyone for any loss or injury caused in whole or in part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting or delivering this e-Newsletter and any information included in this e-Newsletter.
Under no circumstances will the authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" be liable to you or anyone else for any decision made or any action taken by you or anyone else in reliance on such information or view, or for any incidental, consequential, special, or similar damages even if advised of the possibility of such damages.
The above warranties are the only warranties of any kind either expressed or implied, including warranties of merchantability or fitness for any particular purpose.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063